Vincent Verdi, MD
Ophthalmology · Norfolk, VANPI 1053326777
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,231 of the $2,782 with a category attached, or 80.2%. It is spread thinly across 19 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $687 and has fallen 93.2% since, to $46 in 2025.
Across 125 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$630
- Notal Vision, Inc.$433
- Mallinckrodt Hospital Products Inc.$263
- Sun Pharmaceutical Industries Inc.$257
- Biotissue Holdings Inc.$180
- Kala Pharmaceuticals, Inc.$155
- plus $863 from 13 others
What the payments were for
- Speaking & faculty fees$43316%
- Food & beverage$2,23180%
- Education$1184%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $630 |
| Notal Vision, Inc. | 2 | $433 |
| Mallinckrodt Hospital Products Inc. | 7 | $263 |
| Sun Pharmaceutical Industries Inc. | 12 | $257 |
| Biotissue Holdings Inc. | 8 | $180 |
| Kala Pharmaceuticals, Inc. | 8 | $155 |
| Alcon | 6 | $140 |
| Novartis | 7 | $137 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $134 |
| Aerie Pharmaceuticals, Inc. | 6 | $97 |
| Mallinckrodt Enterprises LLC | 4 | $83 |
| Dompe US, Inc. | 2 | $71 |
| Tarsus Pharmaceuticals, Inc. | 2 | $49 |
| Harrow Eye, LLC | 2 | $41 |
| Bausch & Lomb Americas Inc. | 2 | $37 |
| Amgen | 1 | $23 |
| Shire North American Group Inc | 1 | $18 |
| Omeros Corporation | 1 | $18 |
| Oasis Medical, Inc. | 1 | $15 |
How this compares
$2,782 in reported general payments places this provider in the 75th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 97 | $55,714 |
| RestasisCyclosporine | 41 | $46,939 |
| CombiganBrimonidine Tartrate/Timolol | 70 | $25,474 |
| XiidraLifitegrast | 16 | $24,799 |
| Brimonidine Tartrate | 196 | $16,160 |
| Alphagan PBrimonidine Tartrate | 32 | $15,043 |
| Cyclosporine | 22 | $12,420 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 40 | $7,918 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 23 | $6,667 |
| Travoprost | 32 | $5,172 |
| RhopressaNetarsudil Mesylate | 13 | $4,678 |
| Prednisolone Acetate | 97 | $3,860 |
| Latanoprost | 385 | $3,455 |
| Tobradex StTobramycin/Dexamethasone | 13 | $3,267 |
| Ketorolac Tromethamine | 149 | $3,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $630 | $143,171240 claims |
| Bausch & Lomb Americas Inc.Xiidra | $37 | $24,79916 claims |
| AlconSimbrinza | $140 | $6,66723 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $97 | $4,67813 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $134 | $2,33714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Norfolk
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Kapil KapoorNorfolk$64K
- Albert CheungNorfolk$23K
- Samantha DewundaraNorfolk$19K
- Arielle SpitzeNorfolk$10K
- Rohit AdyanthayaNorfolk$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.